Physician profile
Laura E Sertich
NPI 1457819948
$2,888.12
in general payments reported to CMS, 2019-2025
28 companies · $982 in 2025
The $982 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $466 · 2024: $1,204 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Education: $63.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.53 |
| Education | $63.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $488.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.51 | 2022-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $270.44 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $251.24 | 2022-2025 | Eohilia, Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $225.06 | 2022-2025 | Dupixent |
| Csl Behring | $140.43 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $128.76 | 2023-2025 | |
| Amgen INC. | $105.32 | 2023-2025 | Tezspire |
| Abbvie INC. | $90.08 | 2023-2025 | |
| Octapharma USA, INC. | $73.87 | 2024-2025 | Cutaquig |
| Pharming Healthcare, INC. | $68.78 | 2024-2025 | Ruconest |
| Galderma Laboratories, L.P. | $68.31 | 2025 | Nemluvio |
| Genentech USA, INC. | $65.65 | 2024-2025 | Xolair |
| Grifols USA, LLC | $57.12 | 2024-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $53.98 | 2025 | Neffy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $46.57 | 2025 | Ohtuvayre |
| Incyte Corporation | $44.22 | 2023-2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $36.49 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $30.81 | 2022-2024 | Orladeyo |
| Phathom Pharmaceuticals, INC. | $30.36 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $25.21 | 2022 | |
| Azurity Pharmaceuticals, INC. | $25.11 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $24.02 | 2024 | Ryaltris |
| Kedrion Biopharma, INC. | $22.03 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Lilly USA, LLC | $20.46 | 2025 | Ebglyss |
| Kaleo, INC. | $16.29 | 2023 | Auvi-Q |
| Pfizer INC. | $15.17 | 2025 | |
| Leo Pharma INC. | $14.89 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sertich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.